Literature DB >> 4000197

Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus.

R J Falk, A P Dalmasso, Y Kim, S Lam, A Michael.   

Abstract

We developed a radioimmunoassay to measure the attack complex of complement (SC5b-9) in serum from patients with systemic lupus erythematosus. The radioimmunoassay used a monoclonal antibody to an antigen of C9, which is absent from native C9 but present on SC5b-9. SC5b-9 was detectable in 13 of 63 normal subjects, with a mean value of 0.5 unit (range, 0 to 4.8), and elevated in 13 of 14 patients with active lupus. Analysis of 108 samples from the patients with lupus revealed a mean value of 10.1 units (range, 0 to 35) when the disease was active and 1.0 unit (range, 0 to 433) when it was clinically stable. SC5b-9 was a more sensitive measure of disease activity than C3, C4, or CH50; its specificity was equivalent to that of C3 and C4. SC5b-9 was elevated in serum from 6 of 49 patients with other forms of glomerulonephritis. Our study documents the presence of SC5b-9 in abnormal serum and correlates its elevation with clinical disease activity in patients with active systemic lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4000197     DOI: 10.1056/NEJM198506203122502

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  25 in total

1.  Elevated serum levels of soluble membrane cofactor protein (CD46, MCP) in patients with systemic lupus erythematosus (SLE).

Authors:  M Kawano; T Seya; I Koni; H Mabuchi
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

Review 2.  Pleuropulmonary manifestations of systemic lupus erythematosus.

Authors:  M P Keane; J P Lynch
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

Review 3.  Complement as a source of biomarkers in systemic lupus erythematosus: past, present, and future.

Authors:  Chau-Ching Liu; Joseph M Ahearn; Susan Manzi
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

4.  Detection of the terminal fluid-phase complement complex, SC5b-9, in the plasma of patients with insulin-dependent (type I) diabetes mellitus. Relation to increased urinary albumin excretion and plasma von Willebrand factor.

Authors:  G Triolo; E Giardina; D Casiglia; G Scarantino; G D Bompiani
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

Review 5.  Review: assessment of complement activation in clinical immunology laboratories: time for reappraisal?

Authors:  M Peakman; G Senaldi; D Vergani
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

6.  Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.

Authors:  Amy H Kao; Jeannine S Navratil; Margie J Ruffing; Chau-Ching Liu; Douglas Hawkins; Kathleen M McKinnon; Natalya Danchenko; Joseph M Ahearn; Susan Manzi
Journal:  Arthritis Rheum       Date:  2010-03

Review 7.  Functions and relevance of the terminal complement sequence.

Authors:  S Bhakdi; F Hugo; J Tranum-Jensen
Journal:  Blut       Date:  1990-06

8.  Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus.

Authors:  G Senaldi; V A Makinde; D Vergani; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1988-11       Impact factor: 19.103

9.  Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus.

Authors:  Wilmer L Sibbitt; William M Brooks; Mario Kornfeld; Blaine L Hart; Arthur D Bankhurst; Carlos A Roldan
Journal:  Semin Arthritis Rheum       Date:  2009-10-31       Impact factor: 5.532

Review 10.  New advances in measurement of complement activation: lessons of systemic lupus erythematosus.

Authors:  Chau-Ching Liu; Susan Manzi; Natalya Danchenko; Joseph M Ahearn
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.